Interventions of Interest
- tolebrutinib (Sanofi)
For questions please contact Becca Piltch, Program Manager, bpiltch@icer.org.
View the Key Stakeholder List.
Multiple Sclerosis: SPMS
An assessment of tolebrutinib
Public Meeting
June 2025
Assessment Status
Open
Upcoming Milestone
Revised Scoping DocumentView
Main Review
June 13, 2025
New England CEPAC
The CTAF’s 2025 public meeting on tolebrutinib
Public Comment Period
See Full Timeline
11/19/2024 - 12/10/2024
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
Multiple Sclerosis: RRMS and PPMS
Feb 2017Multiple Sclerosis: SPMS
May 2019
12/18/2024
Revised Scoping Document
01/08/2025
Research Protocol
Please find the research protocol here:
02/24/2025
Model Analysis Plan
05/29/2025
Evidence Report
06/13/2025
Evidence Presentation
07/15/2025
Public Comments
OpenView
Closed